Your browser doesn't support javascript.
loading
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla, John; Ramchandren, Radhakrishnan; Santoro, Armando; Paszkiewicz-Kozik, Ewa; Gasiorowski, Robin; Johnson, Nathalie A; Fogliatto, Laura Maria; Goncalves, Iara; de Oliveira, Jose S R; Buccheri, Valeria; Perini, Guilherme F; Goldschmidt, Neta; Kriachok, Iryna; Dickinson, Michael; Komarnicki, Mieczyslaw; McDonald, Andrew; Ozcan, Muhit; Sekiguchi, Naohiro; Zhu, Ying; Nahar, Akash; Marinello, Patricia; Zinzani, Pier Luigi.
Afiliação
  • Kuruvilla J; Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: john.kuruvilla@uhn.ca.
  • Ramchandren R; Department of Medicine, University of Tennessee, Knoxville, TN, USA.
  • Santoro A; Humanitas University, Department of Biomedical Sciences, Milan, Italy.
  • Paszkiewicz-Kozik E; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Gasiorowski R; Concord Hospital, University of Sydney, Sydney, NSW, Australia.
  • Johnson NA; Jewish General Hospital Montreal, Montreal, QC, Canada.
  • Fogliatto LM; Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.
  • Goncalves I; Fundação Pio XII-Hospital de Câncer de Barretos, São Paulo, Brazil.
  • de Oliveira JSR; Casa de Saude Santa Marcelina, São Paulo, Brazil.
  • Buccheri V; Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Perini GF; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Goldschmidt N; Hadassah Medical Center, Jerusalem, Israel.
  • Kriachok I; National Cancer Institute, Kiev, Ukraine.
  • Dickinson M; Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Komarnicki M; Szpital Kliniczny im Przemienienia, Poznan, Poland.
  • McDonald A; Pretoria East Hospital, Pretoria, South Africa.
  • Ozcan M; Ankara University School of Medicine, Ankara, Turkey.
  • Sekiguchi N; Department of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
  • Zhu Y; Concord Hospital, Merck & Co, Kenilworth, NJ, USA.
  • Nahar A; Concord Hospital, Merck & Co, Kenilworth, NJ, USA.
  • Marinello P; Concord Hospital, Merck & Co, Kenilworth, NJ, USA.
  • Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Lancet Oncol ; 22(4): 512-524, 2021 04.
Article em En | MEDLINE | ID: mdl-33721562
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Anticorpos Monoclonais Humanizados / Brentuximab Vedotin / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Anticorpos Monoclonais Humanizados / Brentuximab Vedotin / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2021 Tipo de documento: Article